Navigation Links
Australian team reveals world-first discovery in a 'floppy baby' syndrome

In a world first, West Australian scientists have cured mice of a devastating muscle disease that causes a Floppy Baby Syndrome a breakthrough that could ultimately help thousands of families across the globe.

The research, published online today in the Journal of Cell Biology, reveals how a team at the Western Australian Institute for Medical Research (WAIMR) has restored muscle function in mice with one type of Floppy Baby Syndrome a congenital myopathy disorder that causes babies to be born without the ability to properly use their muscles.

The currently incurable genetic diseases render most of the affected children severely paralysed and take the lives of the majority of these children before the age of one.

Dr Kristen Nowak, lead author on the publication, said the team was extremely encouraged that it had been able to cure a group of mice born with the condition.

"The mice with Floppy Baby Syndrome were only expected to live for about nine days, but we managed to cure them so they were born with normal muscle function, allowing them to live naturally and very actively into old age," she said.

"This is an important step towards one day hopefully being able to better the lives of human patients mice who were cured of the disease lived more than two years, which is very old age for a mouse."

Dr Nowak said the team was able to cure the mice with the recessive form of the genetic condition by replacing missing skeletal muscle actin a protein integral in allowing muscles to contract with similar actin found in the heart.

"Earlier in our search to tackle these diseases, we discovered a number of children who, despite having no skeletal muscle actin in their skeletal muscle due to their genetic mutation, were not totally paralysed at birth," she said.

"On closer inspection, we found it was because heart actin another form of the protein was abnormally "switched on" in their skeletal muscles.

"We had already begun investigating whether we could use heart actin to treat skeletal muscle actin disease, so that discovery spurred us on, and we've now proved it can be done we can use heart actin to overcome the absence of skeletal muscle actin in mice."

Heart actin is found in cardiac muscle and, during foetal development, it also works in skeletal muscles in the body, but by birth, heart actin has almost completely disappeared within skeletal muscle.

Using genetic techniques, the WAIMR research team has reactivated the heart actin after birth in place of skeletal muscle actin, reversing the effects of the congenital myopathy.

Head of the WAIMR research group Professor Nigel Laing said the team's next step was to apply their findings to human patients.

"We are now screening more than a thousand already-approved medications looking for one that might increase heart actin in skeletal muscles, which could potentially offer a treatment for many patients," he said.

"Current therapies only target the effects of these conditions, not the condition itself we hope our approach could lead to a much greater improvement for a range of muscle diseases."

This discovery is the latest for the team which has been investigating debilitating muscle diseases for more than 20 years.

The first major breakthrough for actin disease was in 1999, when the team identified that defects in the skeletal muscle actin gene, ACTA1 responsible for producing skeletal muscle actin, cause multiple muscle diseases.

Since then, the team has classified and named a new muscle disease 'Laing Myopathy' named after Professor Nigel Laing and helped implement world-wide screening for families at risk of genetic muscle disease.

WAIMR Director Professor Peter Klinken said he was thrilled WAIMR was playing such an integral part in helping tackle devastating muscle diseases.

"The persistence and determination shown by Professor Laing and his team over many, many years is nothing short of inspiring," he said.

"They've asked some big questions in their quest to find a cure for this Floppy Baby Syndrome and have worked tirelessly to find the answers to those questions in the hope of helping families across the world.

"Research institutes like ours exist to help people live healthier lives and I am delighted at the important discoveries we are making in this field."

This research has been funded by the National Health and Medical Research Council, WAIMR and a number of patient support groups including the Association Franaise contre les Myopathies (French Muscular Dystrophy Association) and the US Muscular Dystrophy Association.

The research project centred at the WAIMR laboratory was a collaborative effort with groups at the Medical Research Council and the University of Oxford in the United Kingdom, Cincinnati Children's Hospital Medical Center as well as the Centre for Microscopy, Characterisation and Analysis at the University of Western Australia and Perth-based Proteomics International which have also assisted the team's work.

Floppy Baby Syndrome

The skeletal muscle actin mutations which cause congenital myopathies can be classified into five individual diseases which affect thousands of families worldwide. Children with recessive muscle actin diseases have no skeletal muscle actin because of mutations in the skeletal muscle actin gene which "knock out" the gene function. In Australia, dozens of families are affected by congenital myopathies which bring high emotional costs and personal suffering, as well as financial and community burdens.


Contact: Natalie Papadopoulos
Research Australia

Related medicine news :

1. Australian clinical trials threatened: Jobs and patient access to new treatments at stake
2. MTF, Largest Tissue Bank, Provides Skin for Victims of Australian Wildfires
3. Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
4. Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing
5. ATS Medical Announces Australian Regulatory Approval for ATS 3f Aortic Bioprosthesis
6. Australian technology in global health toolkit
7. Mottram Honours His End of the HBA Great Australian Run challenge
8. HBA People Walk the Talk for Better Health in the HBA Great Australian Run
9. Indigenous Australian patients confused and frustrated by kidney disease
10. New Cosmetic Trends Change the Face of the Australian Botox Market
11. Australian over-50s walk away memory problems in world-first trial
Post Your Comments:
(Date:10/13/2015)... ... ... Sir Grout of Greater Boston donated an expansive, seven room tile and ... (RMHC®). This donation was made in an effort to give back to the local ... “We believe strongly in the Ronald McDonald House Charities, and they are truly a ...
(Date:10/13/2015)... , ... October 13, 2015 , ... "My friend's son ... fists into his infected cheeks," said an inventor from Platteville, Colo. "I came up ... problems." , He developed the UNTOUCHABLE to prevent a child from rubbing or scratching ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... pain management services, today announced its partnership with WPC Healthcare , a ... disparate systems and organizes the data into an aggregated data repository necessary to ...
(Date:10/13/2015)... ... , ... According to an article published October 5th by the ... lose weight with a bariatric procedure are much less likely to develop endometrial cancer, ... anywhere from 40 to 50 percent of all endometrial cancer cases are caused by ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec ... their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG Summits to take ... and NAVUG Summit are independent user conferences designed and led by users to ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 2015   Vigilant Biosciences, Inc. ("Vigilant"), a ... the early detection and intervention of cancer, announced today ... CEO, Matthew H.J. Kim , the Weaver H. ... entrepreneur who has made extraordinary contributions to the growth ... in the leadership of a company or institution. ...
(Date:10/13/2015)... Oct. 13, 2015 WuXi PharmaTech (Cayman) ... technology platform company serving the pharmaceutical, biotechnology, and ... launched a mobile version of OncoWuXi, the first ... access oncology models and data on the go.  ... at any time to identify relevant tumor models ...
(Date:10/13/2015)... , Oct. 13, 2015   Happy ... direct-to-consumer laboratory home testing kit for breast ... technologies provide an unparalleled, detailed assessment of ... milk—fats, proteins, carbs and key vitamins—all charted ... for personal health tracking.  In addition, Happy Vitals ...
Breaking Medicine Technology: